Discover how DELFI's innovative blood test leverages cutting-edge genomic technology to help detect lung cancer at earliest stages.
DELFI's FirstLook Lung test identifies genome-wide alterations associated with lung cancer at high sensitivity using a simple blood draw.1,2
Intended for individuals deemed eligible for lung cancer screening by the United States Preventative Services Task Force (USPSTF), FirstLook Lung helps determine the likelihood of detecting lung cancer through Low-Dose Computed Tomography (LDCT).
FirstLook Lung is designed to be a convenient first step in detecting lung cancer early, when it is most treatable.
Leading academic medical centers and integrated delivery networks have partnered with DELFI to implement the FirstLook Lung cancer screening solution and, in some instances, contribute to clinical evidence for early detection programs.
These strategically selected health systems - including several of the nation's most respected healthcare institutions - collaborate with our team to optimize lung cancer screening workflows, improve patient outcomes, and demonstrate their commitment to innovative preventive care.
Their experience showcases how adopting cutting-edge technology can transform cancer screening programs while delivering measurable clinical and operational value.
Our health system partners and collaborators include
(alphabetical order):
FirstLook Lung is a blood-based lung cancer screening test with a comprehensive body of real-world evidence from health system partners.
American Thoracic Society (ATS) Annual Meeting 2026
Reached patients LDCT programs were missing
Most patients who chose the blood test had never been screened or were overdue, and navigation moved elevated results on to LDCT.
American Thoracic Society (ATS) Annual Meeting 2026
Screening rates rose across the program
Offering a blood test alongside LDCT brought more eligible patients into screening, and LDCT use grew at the same time.
Rescue Lung Society Annual Conference 2025
Faster results for patients, quarter after quarter
Time from order to result improved each quarter as AHN refined its blood draw and follow-up workflows.
CHEST Conference 2025
Fits into existing primary care workflows
Built into the EHR with payer coverage, the test was adopted quickly by providers across the network.
American Thoracic Society (ATS) Annual Meeting 2026
Patients chose a blood draw at home
In under-resourced communities, most participants chose at-home testing by mobile phlebotomy, and more of those with an elevated result completed LDCT within six months than those who chose LDCT alone.
American Society of Clinical Oncology (ASCO) Annual Meeting 2026
Another way in for patients behind on screening
FirstLook Lung is one part of a navigator-led, AI-assisted program associated with higher screening rates and earlier diagnosis, including in rural communities.
99.8% negative predictive value and clinically validated for lung cancer2
Earlier detection enables earlier intervention
Treating cancer sooner focuses resources on ensuring better outcomes
Improved patient engagement in early lung cancer detection
Seamless integration into existing healthcare systems with best-practice alerts and advanced EHR integration capabilities
A simple lab test-ordering process; no extensive training or additional equipment is needed
Patient and provider-focused educational materials to support outreach teams
This webinar showcases how innovative health systems like OSF Healthcare and Allegheny Health Network are transforming their lung cancer screening programs by implementing the FirstLook Lung test from DELFI Diagnostics. FirstLook is a blood-based test that uses artificial intelligence and genomics to enable a convenient, in-office start to lung cancer screening. Through real-world case studies, speakers share their diverse approaches to expanding screening access, improving care delivery efficiency, and achieving population health goals.
Medical Director of Aerodigestive Research at Allegheny Singer Research Institute
Vice President, Community Medicine Service Line at OSF HealthCare Multispecialty Services
Schedule a meeting with our partnership executives to discuss how our innovative genomics solution with FirstLook can become part of your lung cancer screening program. Learn about the applications of fragmentomics research and non-invasive cancer testing.
Let us help you take the next steps in improving your organization's patient care and resource allocation through next-generation blood-based tests and cfDNA testing.
References: 1. Mazzone, P.J., Bach, P.B., Carey, J., et al. Cancer Discovery. 10.1158 – 2159-8290. CD-24-0519. (2024). 2. Unpublished data on file.
FirstLook Lung is intended to be an adjunct, qualitative aid evaluating adults eligible for LDCT lung cancer screening. It is designed to supplement, not supplant, recommended screening tests for lung cancer in the population described in the Indications for Use, including LDCT examination.
The FirstLook Lung test is a laboratory-developed test. It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high complexity clinical tests. This test is used for clinical purposes. It should not be regarded as investigational or for research.
FirstLook is a trademark of DELFI Diagnostics, Inc. used worldwide.
